HRMY Q1 2022 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$85M+43.0% YoY

Gross Profit

$71M82.8% margin

Operating Income

$28M32.3% margin

Net Income

$21M25.2% margin

EPS (Diluted)

$0.35

QoQ Revenue Growth

-6.5%

Cash Flow

Operating Cash Flow

$29M

Free Cash Flow

$29M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$464M

Total Liabilities

$250M

Stockholders' Equity

$215M

Cash & Equivalents

$224M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$85M	$60M	+43.0%
Gross Profit	$71M	$49M	+43.3%
Operating Income	$28M	$15M	+89.6%
Net Income	$21M	$7M	+190.9%

Geographic Segments

United States

$500M100%